Angélique Pabois

Angélique Pabois

Auto-generated profile, based on publicly available information

Angélique Pabois

INSERM UMR1064, Nantes University Hospital, Nantes, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2017 in OncoImmunology
Verified
Journal Article
Open access
RTRiccardo Turrini
Riccardo Turrini
APAngélique Pabois
Angélique Pabois
IXIoannis Xenarios
Ioannis Xenarios
GCGeorge Coukos
George Coukos
JDJean-François Delaloye
Jean-François Delaloye
MDMarie-Agnès Doucey
Marie-Agnès Doucey
Tumor-associated macrophages (TAM) are well known as a key player in the tumor microenvironment, which support cancer progression. More recently, a lineage of monocytes characterized by the expression of the TIE-2/Tek angiopoietin receptor identified a subset of circulating and tumor-associated monocytes endowed with proangiogenic activity. TIE-2 expressing monocytes (TEM) were found both in humans and mice. Here, we review the phenotypes and functions of TEM reported so far in human cancer and their potential use as markers of cancer progression and metastasis. Finally, we discuss the therapeutic approaches currently used or proposed to target TEM.

1 March 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
APAngélique Pabois
Angélique Pabois
SPSylvain Pagie
Sylvain Pagie
NGNathalie Gérard
Nathalie Gérard
CLChristian Laboisse
Christian Laboisse
SPSabine Pattier
Sabine Pattier
Beatrice CharreauBeatrice Charreau
Beatrice Charreau

15 October 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LMLaia Martínez-Carreres
Laia Martínez-Carreres
JPJulien Puyal
Julien Puyal
LLLucía C. Leal-Esteban
Lucía C. Leal-Esteban
MOMeritxell Orpinell
Meritxell Orpinell
JCJudit Castillo-Armengol
Judit Castillo-Armengol
Lluis FajasLluis Fajas
Lluis Fajas
Cyclin-dependent kinase 4 (CDK4) is well-known for its role in regulating the cell cycle, however, its role in cancer metabolism, especially mTOR signaling, is undefined. In this study, we established a connection between CDK4 and lysosomes, an emerging metabolic organelle crucial for mTORC1 activation. On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. On the other hand, CDK4 directly regulated lysosomal function and was essential for lysosomal degradation, ultimately regulating mTORC1 activity. Pharmacologic inhibition or genetic inactivation of CDK4, other than retaining FLCN at the lysosomal surface, led to the accumulation of undigested material inside lysosomes, which impaired the autophagic flux and induced cancer cell senescence in vitro and in xenograft models. Importantly, the use of CDK4 inhibitors in therapy is known to cause senescence but not cell death. To overcome this phenomenon and based on our findings, we increased the autophagic flux in cancer cells by using an AMPK activator in combination with a CDK4 inhibitor. The cotreatment induced autophagy (AMPK activation) and impaired lysosomal function (CDK4 inhibition), resulting in cell death and tumor regression. Altogether, we uncovered a previously unknown role for CDK4 in lysosomal biology and propose a novel therapeutic strategy to target cancer cells. Significance: These findings uncover a novel function of CDK4 in lysosomal biology, which promotes cancer progression by activating mTORC1; targeting this function offers a new therapeutic strategy for cancer treatment.

12 May 2025 in Nature Immunology
Verified
Journal Article
Open access
PDF file
TSTheodore J. Sanders
Theodore J. Sanders
CNChristopher S. Nabel
Christopher S. Nabel
MBMargreet Brouwer
Margreet Brouwer
AHAnnelise L. Hermant
Annelise L. Hermant
LCLucas Chaible
Lucas Chaible
EHErica Houthuys
Erica Houthuys
The benefit of immune checkpoint blockade for cancer therapy is limited to subsets of patients because of factors including the accumulation of immunosuppressive metabolites, such as adenosine, within tumors. Pharmacological inhibition of adenosine generation and signaling is an active area of clinical investigation, but only limited clinical benefit has been reported. Here, we show that adenosine suppresses anti-cancer T cell responses following uptake into activated T cells by equilibrative nucleoside transporter 1 (ENT1) and inhibition of de novo pyrimidine nucleotide synthesis. We identify EOS301984 as a potent ENT1 antagonist that restores pyrimidine levels in activated T cells in adenosine-rich environments, resulting in enhanced tumor cell killing by memory T cells and increased ex vivo expansion of functional human tumor-infiltrating lymphocytes. A combination of EOS301984 with anti-PD-1 led to synergistic control of tumor growth in a humanized mouse model of triple-negative breast cancer. ENT1 inhibition, therefore, augments anti-cancer immune responses through the restoration of pyrimidine nucleotide synthesis in T cells suppressed by adenosine.

16 July 2013 in Journal of Innate Immunity
Verified
Journal Article
Closed access
PDF file
ACAnnabelle Chauveau
Annabelle Chauveau
PTPierre TONNERRE
Pierre TONNERRE
APAngélique Pabois
Angélique Pabois
PGPierre-Jean Gavlovsky
Pierre-Jean Gavlovsky
MCMathais Chatelais
Mathais Chatelais
Beatrice CharreauBeatrice Charreau
Beatrice Charreau
MICA are major histocompatibility complex class I-related molecules, expressed by endothelial cells (ECs), that may be targets for alloantibodies and NKG2D-expressing natural killer (NK) and T effector cells in organ allografts. This study shows that basal levels of MICA expressed on vascular ECs is sufficient to functionally modulate the expression and activity of the immunoreceptor NKG2D in allogeneic NK cells. We found that MICA expression is differentially regulated at the EC surface in response to cytokines. TNFa upregulates MICA while IFNγ significantly decreases MICA at the EC surface. Both cytokines induce the release of soluble MICA by ECs. Modulation of NKG2D correlates with the MICA level on the EC surface. Glycosylation and metalloproteinase activities account for major post-transcriptional mechanisms controlling MICA level and the function in ECs. Our results indicate that, in addition to the NFγB pathway, the mitogen-activated protein kinase pathways JNK, ERK1/2 and p38 are key signaling pathways in the control of MICA by the cytokines. Finally, we show that EC proliferation mediated by FGF-2 or wound healing increases the MICA level. Together, our data suggest that inflammation and proliferation regulate endothelial MICA expression and shedding, enabling ECs to modulate NKG2D activity on effector NK and T cells, and provide further evidence of a role for ECs in immunoregulation.

24 August 2015 in Journal of Natural Products
Verified
Journal Article
Closed access
CRCaroline Rouger
Caroline Rouger
SDSéverine Derbré
Séverine Derbré
Beatrice CharreauBeatrice Charreau
Beatrice Charreau
APAngélique Pabois
Angélique Pabois
TCThomas Cauchy
Thomas Cauchy
PRPascal Richomme
Pascal Richomme